These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 19373888

  • 1. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.
    Weinstein SM, Messina J, Xie F.
    Cancer; 2009 Jun 01; 115(11):2571-9. PubMed ID: 19373888
    [Abstract] [Full Text] [Related]

  • 2. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM, Messina J, Xie F, Hale M.
    Clin Ther; 2007 Apr 01; 29(4):588-601. PubMed ID: 17617282
    [Abstract] [Full Text] [Related]

  • 3. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
    Slatkin NE, Xie F, Messina J, Segal TJ.
    J Support Oncol; 2007 Apr 01; 5(7):327-34. PubMed ID: 17708123
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T.
    Clin Ther; 2009 Jun 01; 31(6):1177-91. PubMed ID: 19695386
    [Abstract] [Full Text] [Related]

  • 6. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
    Portenoy RK, Messina J, Xie F, Peppin J.
    Curr Med Res Opin; 2007 Jan 01; 23(1):223-33. PubMed ID: 17207304
    [Abstract] [Full Text] [Related]

  • 7. Fentanyl buccal tablet.
    Messina J, Darwish M, Fine PG.
    Drugs Today (Barc); 2008 Jan 01; 44(1):41-54. PubMed ID: 18301803
    [Abstract] [Full Text] [Related]

  • 8. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain.
    Webster LR, Messina J, Xie F, Nalamachu S.
    J Opioid Manag; 2011 Jan 01; 7(4):297-308. PubMed ID: 21957829
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain.
    Zeppetella G, Messina J, Xie F, Slatkin NE.
    Pain Pract; 2010 Jan 01; 10(4):287-93. PubMed ID: 20230447
    [Abstract] [Full Text] [Related]

  • 11. Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients.
    Nalamachu SR, Narayana A, Janka L.
    Curr Med Res Opin; 2011 Apr 01; 27(4):751-60. PubMed ID: 21288055
    [Abstract] [Full Text] [Related]

  • 12. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study.
    Fine PG, Messina J, Xie F, Rathmell J.
    J Pain Symptom Manage; 2010 Nov 01; 40(5):747-60. PubMed ID: 20594801
    [Abstract] [Full Text] [Related]

  • 13. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain.
    Ashburn MA, Slevin KA, Messina J, Xie F.
    Anesth Analg; 2011 Mar 01; 112(3):693-702. PubMed ID: 21304148
    [Abstract] [Full Text] [Related]

  • 14. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management.
    Fine PG, Narayana A, Passik SD.
    Pain Med; 2010 Jul 01; 11(7):1024-36. PubMed ID: 20642730
    [Abstract] [Full Text] [Related]

  • 15. A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain.
    Farrar JT, Messina J, Xie F, Portenoy RK.
    Pain Med; 2010 Sep 01; 11(9):1313-27. PubMed ID: 20807345
    [Abstract] [Full Text] [Related]

  • 16. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
    Kosugi T, Hamada S, Takigawa C, Shinozaki K, Kunikane H, Goto F, Tanda S, Shima Y, Yomiya K, Matoba M, Adachi I, Yoshimoto T, Eguchi K.
    J Pain Symptom Manage; 2014 Jun 01; 47(6):990-1000. PubMed ID: 24099893
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
    Rauck RL, Tark M, Reyes E, Hayes TG, Bartkowiak AJ, Hassman D, Nalamachu S, Derrick R, Howell J.
    Curr Med Res Opin; 2009 Dec 01; 25(12):2877-85. PubMed ID: 19814586
    [Abstract] [Full Text] [Related]

  • 18. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R, Kayser H, Sittl R.
    Clin Ther; 2006 Jun 01; 28(6):943-52. PubMed ID: 16860176
    [Abstract] [Full Text] [Related]

  • 19. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ, Nurmikko TJ, Young CA.
    Clin Ther; 2007 Sep 01; 29(9):2068-79. PubMed ID: 18035205
    [Abstract] [Full Text] [Related]

  • 20. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
    Webster LR, Slevin KA, Narayana A, Earl CQ, Yang R.
    Pain Med; 2013 Sep 01; 14(9):1332-45. PubMed ID: 23855816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.